REG-Lilly (Eli) & Co: STATEMENT ON FDA'S BYETTA (EXENATIDE) INJECTION UPDATE

Media contacts: Amylin - Anne Erickson

Phone: (858) 754-4443

Cell: (858) 349-3195

Email: anne.erickson@amylin.com

Lilly - Kindra Strupp

Phone: (317) 277-5170

Cell: (317) 554-9577

Email: kstrupp@lilly.com

AmyLIN PHARMACEUTICALS AND eli LILLY And Company statement on
FDA's byetta® (EXENATIDE) injection update

SAN DIEGO and INDIANAPOLIS - Nov. 2, 2009 - Amylin Pharmaceuticals, Inc.,
(Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today issued the following
statement in response to the U.S. Food and Drug Administration (FDA) update on
BYETTA® (exenatide) injection.

"The FDA update issued today aligns with the BYETTA label approved last week.
The current label reflects our understanding of post-marketing reports of renal
events and provides physicians with updated guidance about appropriate use in
patients with renal conditions. There is no evidence from preclinical and
clinical studies that BYETTA has any direct toxic effect on the kidney," said
Orville G. Kolterman, M.D., senior vice president of research and development,
Amylin Pharmaceuticals. "Post-marketing reports of serious changes in renal
function have been rare and usually complicated by other factors that could
have contributed to the kidney problems. It is also important to note that
diabetes is the leading cause of kidney failure. Information about use of
BYETTA in patients with impaired renal function was included in the initial
product label in 2005 and was updated in 2007. We remain committed to working
closely with the FDA to ensure that physicians and patients are provided with
accurate information about any potential risks associated with the use of our
products."

On October 30, the FDA approved an expanded indication for BYETTA as a
stand-alone medication (monotherapy) along with diet and exercise to improve
glycemic control in adults with type 2 diabetes. In addition to the monotherapy
indication, the FDA approved changes to the BYETTA Prescribing Information to
incorporate updated safety information. The new label expands upon existing
language regarding use of BYETTA in patients with renal impairment, which
Amylin and Lilly updated in September 2007 to include additional language
regarding renal adverse events. It specifies that BYETTA should not be used in
patients with severe renal impairment or end-stage renal disease and should be
used with caution in patients with renal transplantation. It also specifies
that because BYETTA may induce nausea and vomiting with transient hypovolemia
(low blood volume), treatment may worsen renal function. This update was
communicated to physicians via a "Dear Healthcare Professional" letter, which
is available at www.BYETTA.com.

BYETTA has extensive post-marketing experience and a well-documented safety
profile. BYETTA has been used by more than one million patients since market
introduction in 2005. It has a proven history with more than 10 million
prescriptions written and 6.5 years of clinical experience.

About Diabetes

Diabetes affects more than 24 million people in the United States and an
estimated 246 million adults worldwide., Approximately 90-95 percent of those
affected have type 2 diabetes. Diabetes is the fifth leading cause of death by
disease in the United States and costs approximately $174 billion per year in
direct and indirect medical expenses.

According to the Centers for Disease Control and Prevention's National Health
and Nutrition Examination Survey, approximately 60 percent of people with
diabetes do not achieve their target blood sugar levels with their current
treatment regimen. In addition, 85 percent of type 2 diabetes patients are
overweight and 55 percent are considered obese. Data indicate that weight loss
(even a modest amount) supports patients in their efforts to achieve and
sustain glycemic control.,

About BYETTA® (exenatide) injection

BYETTA is the first and only FDA-approved GLP-1 receptor agonist for the
treatment of type 2 diabetes. BYETTA exhibits many of the same effects as the
human incretin hormone glucagon-like peptide-1 (GLP-1). GLP-1 improves blood
sugar after food intake through multiple effects that work in concert on the
stomach, liver, pancreas and brain.

BYETTA is an injectable prescription medicine that may improve blood sugar
(glucose) control in adults with type 2 diabetes mellitus, when used with a
diet and exercise program. BYETTA is not insulin and should not be taken
instead of insulin. BYETTA is not recommended to be taken with insulin. BYETTA
is not for people with type 1 diabetes or people with diabetic ketoacidosis.

BYETTA provides sustained A1C control and low incidence of hypoglycemia when
used alone or in combination with metformin or a thiazolidinedione, with
potential weight loss. BYETTA is not a weight loss product. BYETTA was approved
in April 2005 and has been used by more than one million patients since its
introduction. For full prescribing information, visit www.BYETTA.com.

Important Safety Information for BYETTA® (exenatide) injection
Based on post-marketing data, BYETTA has been associated with acute
pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing
pancreatitis. The risk for getting low blood sugar is higher if BYETTA is taken
with another medicine that can cause low blood sugar, such as a sulfonylurea.
BYETTA should not be used in people who have severe kidney problems, and should
be used with caution in people who have had a kidney transplant. Patients
should talk with their healthcare provider if they have severe problems with
their stomach, such as delayed emptying of the stomach (gastroparesis) or
problems with digesting food. Severe allergic reactions can happen with BYETTA.

The most common side effects with BYETTA include nausea, vomiting, diarrhea,
dizziness, headache, feeling jittery, and acid stomach. Nausea most commonly
happens when first starting BYETTA, but may become less over time.

These are not all the side effects from use of BYETTA. A healthcare provider
should be consulted about any side effect that is bothersome or does not go
away.

For Prescribing Information and Medication Guide, visit www.BYETTA.com.

About Amylin and Lilly

Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving
lives of patients through the discovery, development and commercialization of
innovative medicines. Amylin has developed and gained approval for two
first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection
and BYETTA® (exenatide) injection. Amylin's research and development activities
leverage the Company's expertise in metabolism to develop potential therapies
to treat diabetes and obesity. Amylin is headquartered in San Diego,
California. Further information on Amylin Pharmaceuticals is available at
www.amylin.com.

Through a long-standing commitment to diabetes care, Lilly seeks to provide
patients with breakthrough treatments that enable them to live longer,
healthier, and fuller lives. Since 1923, Lilly has been an industry leader in
pioneering therapies to help healthcare professionals improve the lives of
people with diabetes, and research continues on innovative medicines to address
the unmet needs of patients. For more information about Lilly's current
diabetes products, visit www.lillydiabetes.com.

Lilly, a leading innovation-driven corporation, is developing a growing
portfolio of pharmaceutical products by applying the latest research from its
own worldwide laboratories and from collaborations with eminent scientific
organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -
through medicines and information - for some of the world's most urgent medical
needs. Additional information about Lilly is available at www.lilly.com.

This press release contains forward-looking statements about Amylin and Lilly.
Actual results could differ materially from those discussed or implied in this
press release due to a number of risks and uncertainties, including the risk
that BYETTA and the revenues generated from BYETTA may be affected by
competition; unexpected new data; safety and technical issues; clinical trials
not confirming previous results; pre-clinical trials not predicting future
results; label expansion requests not being submitted in a timely manner or
receiving regulatory approval; approved label expansions not producing the
results we expect, or manufacturing and supply issues. The potential for BYETTA
may also be affected by government and commercial reimbursement and pricing
decisions, the pace of market acceptance, or scientific, regulatory and other
issues and risks inherent in the commercialization of pharmaceutical products.
These and additional risks and uncertainties are described more fully in
Amylin's and Lilly's most recent SEC filings including their Quarterly Reports
on Form 10-Q and Annual Reports on Form 10-K. Amylin and Lilly undertake no
duty to update these forward-looking statements.

P-LLY

# # #

The International Diabetes Federation Diabetes Atlas. Available at: http://
www.idf.org/home/index.cfm?unode=3B96906B-C026-2FD3-87B73F80BC22682A. Accessed
Oct. 2, 2009.

"All About Diabetes." American Diabetes Association. Available at: http://
www.diabetes.org/about-diabetes.jsp. Accessed Oct. 2, 2009.

"Direct and Indirect Costs of Diabetes in the United States." American Diabetes
Association. Available at: http://www.diabetes.org/diabetes-statistics/
cost-of-diabetes-in-us.jsp. Accessed Oct. 2, 2009.

Saydah SH, Fradkin J and Cowie CC. Poor control of risk factors for vascular
disease among adults with previously diagnosed diabetes. JAMA. 2004;291:335-42.

Bays HE, Chapman RH, Grandy S. The relationship of body mass index to diabetes
mellitus, hypertension and dyslipidaemia: comparison of data from two national
surveys. Int J Clin Pract. 2007;61:737-47.

Nutrition Recommendations and Interventions for Diabetes: a position statement
of the American Diabetes Association. Diabetes Care. 2007;30 Suppl 1:S48-65.

viii Anderson JW, Kendall CW, Jenkins DJ. Importance of weight management in
type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr.
2003;22:331-9.

END